In the US, life science industry research and advisory firm BioInformatics has hired three key members of staff at its Arlington, VA office: Jessica McLaughlin, Vincent Slay and Elizabeth Hood.
The firm taps into a network of tens of thousands of scientists and biomedical professionals to offer insights for clients. Services include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
McLaughlin joins as Qual Research Project Manager with more than twenty years of experience of healthcare and pharma sector market research. Most recently, she worked at Lieberman Research Group as Senior Research Analyst, and earlier spent nearly a decade in MR consultancy roles at Reston, VA-based healthcare and pharma research firm The Dominion Group. In her new role, she will support clients with qualitative research planning, interviewing, content analysis and actionable reporting.
Slay takes up the position of Account Director, with twelve years' pharmaceutical sales and five years' medical device sales, most recently with Becton Dickinson. At BioInformatics, Slay will work with clients to understand their business objectives and develop appropriate research strategies.
Hood becomes Senior Data Analyst, with a background in developing research objectives, questionnaire design, quant methods, data analysis and report writing. She is also a qualitative researcher and has experience with both Computer Assisted Personal Interviewing (CAPI) and face-to-face interviewing.
CEO Craig Overpeck (pictured) comments: 'These three individuals are outstanding additions to our already talented team. Their experience, together with our improved set of research methodologies and advanced statistical tools, enable us to continue to partner with clients and provide even deeper insights to all of our engagements'.
Web site: www.gene2drug.com .
All articles 2006-18 written and edited by Mel Crowther and/or Nick Thomas.